Search | Clinical Trials Finder

Conditions: Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor, Recurrent Gastrointestinal Stromal Tumor, Refractory Malignant Gastrointestinal Stromal Tumor, Unresectable Malignant Gastrointestinal Stromal Tumor
Interventions: Aldesleukin, Biospecimen Collection, Chest Radiography, Computed Tomography, Cyclophosphamide, Echocardiography Test, Filgrastim, Fludarabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Surgical Procedure, Tumor Infiltrating Lymphocyte Therapy; Biological · Procedure · Drug
Lead sponsor: Joal Beane; Other
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Obstructive Sleep Apnea
Interventions: Lumbar Puncture (Standard-of-Care); Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 50 Years to 84 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Ponatinib, Prednisone, Rituximab, Vincristine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography; Drug · Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions: filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, autologous bone marrow transplantation, bone marrow ablation with stem cell support; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 16 Years to 120 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hematologic Neoplasms
Interventions: Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine, Sirolimus, Filgrastim, Cyclophosphamide, Mesna, Total Body Irradiation (TBI); Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 85 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Sarcoma
Interventions: filgrastim, ifosfamide, peripheral blood stem cell transplantation, Sm-EDTMP (low dose), sm-EDTMP (higher dose); Biological · Drug · Procedure + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 13 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: filgrastim, therapeutic autologous lymphocytes, cyclophosphamide, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Atherosclerosis, Coronary
Interventions: Autologous CD34+ Cells, Granulocyte Colony-Stimulating Factor (G-CSF); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions: G-CSF plus plerixafor, rituximab; Drug · Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 366 Days to 46 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 145
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more

Conditions: Hydrocephalus
Interventions: Rhaeos Shunt Monitoring System; Device
Lead sponsor: Rhaeos, Inc.; Industry
Eligibility: Not listed
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Lumbar puncture, Blood draw, Magnetic Resonance Imaging (MRI); Procedure
Lead sponsor: Emory University; Other
Eligibility: 60 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis
Interventions: Companion blood samples with procedure; Procedure
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more

Conditions: Normal Physiology
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Delirium, Hip Arthroplasty, Elderly
Interventions: Blood Draw, Cerebral Spinal Fluid collection, Electroencephalogram, Cerebral blood flow and oxygen extraction fraction; Procedure · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 65 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: Filgrastim, Cladribine, Cyclosporine, Cytarabine (Ara-C), Fludarabine Phosphate, Idarubicin, Methylprednisolone, Peripheral Blood Stem Cell Transplantation; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 55 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Apheresis Donors, Mononuclear (MNC) Cell Donors
Interventions: Spectra Optia CMNC, COBE Spectra MNC, Granulocyte-colony stimulating factor (G-CSF); Device · Drug
Lead sponsor: Terumo BCT; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Cincinnati, Ohio • Memphis, Tennessee

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: filgrastim, carboplatin, etoposide, isotretinoin, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 52
States / cities: Little Rock, Arkansas • Oakland, California • Sacramento, California + 45 more

Conditions: Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type, Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Filgrastim, Fludeoxyglucose F-18, Multigated Acquisition Scan, Pegfilgrastim, Prednisone, Questionnaire Administration, Ruxolitinib Phosphate, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Non-Hodgkin's Lymphoma, Multiple Myeloma
Interventions: Plerixafor, Filgrastim; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: T-cell Non-Hodgkin Lymphoma
Interventions: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone, Filgrastim, Plerixafor, Stem Cell Collection, Palifermin, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
Interventions: Arm 1; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Sturlimogene Erparepvec, Tivozanib; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Insomnia Chronic
Interventions: lumbar puncture; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 30 Years to 50 Years
Enrollment: 30 participants
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors

A Pilot Study of Biomarkers in Obstructive Sleep Apnea

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma

Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)

Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Flow Detection in Open and Closed Shunt Valve Periods

African American Alzheimer's Progression Markers - CSF and Neuro-Imaging

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers

Delirium, Intraoperative Cerebral Perfusion and EEG Abnormalities After Total Hip Arthroplasty

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

An Evaluation of the Spectra Optia CMNC Collection Procedure

High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Chronic Insomnia and CSF Markers of Dementia